Literature DB >> 1825123

Activation and in vitro expansion of tumor-reactive T lymphocytes from lymph nodes draining human primary breast cancers.

S K Hoover1, J L Frank, C McCrady, J G McKinnon, H D Bear.   

Abstract

The feasibility of in vitro activation of lymphocytes from the draining lymph nodes (DLN) of breast cancer patients was examined. Lymphocytes isolated from 48 DLN from 12 patients were examined for their proliferative responses to rIL-2, autologous tumor cells, or rIL-2 plus tumor cells. Three general patterns of cellular responses were observed. Cells from some DLN (17%) were unresponsive to any stimuli. Lymphocytes from 52% of the DLN responded moderately to rIL-2 alone. The combination of rIL-2 and tumor antigen had a synergistic effect on the proliferation of cells from 31% of the DLN assayed. Phorbol dibutyrate and ionomycin plus rIL-2 stimulated expansion of DLN lymphocytes by up to 850-fold after 35 days. These expanded cell populations, as well as those stimulated with antigen plus rIL-2, were predominantly CD3+ and CD16- cells, varying in proportions of CD4+ and CD8+ subsets. Both populations were cytotoxic against autologous tumor, MCF-7, and K562 target cells.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1825123     DOI: 10.1002/jso.2930460210

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  4 in total

Review 1.  Immunotherapeutic approaches for the treatment of breast cancer.

Authors:  K L Knutson; K Schiffman; K Rinn; M L Disis
Journal:  J Mammary Gland Biol Neoplasia       Date:  1999-10       Impact factor: 2.673

2.  Ex vivo expansion of tumor-draining lymph node cells using compounds which activate intracellular signal transduction. I. Characterization and in vivo anti-tumor activity of glioma-sensitized lymphocytes.

Authors:  N G Baldwin; C D Rice; T M Tuttle; H D Bear; J I Hirsch; R E Merchant
Journal:  J Neurooncol       Date:  1997-03       Impact factor: 4.130

3.  Ex vivo expansion of tumor-draining lymph node cells using compounds which activate intracellular signal transduction. II. Cytokine production and in vivo efficacy of glioma-sensitized lymphocytes.

Authors:  C D Rice; N G Baldwin; R T Biron; H D Bear; R E Merchant
Journal:  J Neurooncol       Date:  1997-03       Impact factor: 4.130

4.  Improved survival with adjuvant immunotherapy after surgical resection in a murine model.

Authors:  L S Hamby; J W Freeman; P C McGrath
Journal:  Ann Surg Oncol       Date:  1994-07       Impact factor: 5.344

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.